Ciclesonide HFA

Phase 3Small molecule

Sumitomo Pharma America, Inc.

Ciclesonide HFA is one of 55 small molecule programs targeting Allergic Rhinitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisActive, not recruiting

Seasonal Allergic RhinitisActive, not recruiting

Allergic RhinitisPhase 3

Active, not recruiting

Seasonal Allergic RhinitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Asmanex Hfa

PPerrigo Company

Phase 3

5 2

Sudafed

KKenvue Brands

Phase 3

3 3

Immunotherapy

Bristol-Myers Squibb

Phase 3

1 4

Elestat

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 5

Asmanex HFA

Sumitomo Pharma America, Inc.

Phase 3

1 6

Allegra-D

Pfizer

Phase 3

3 7

Ciclesonide HFA

Sumitomo Pharma America, Inc.

Phase 3

3 8

Asmanex

Novartis

Preclinical

12 9

Ismigen

LLallemand Pharma AG

Phase 3

1 10

Administration of Comparator

EEurofarma Laboratorios S.A.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Rhinitis3 trials

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00806754·340 enrolled

A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT00953147·1,110 enrolled

A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT01067105·824 enrolled

Seasonal Allergic Rhinitis2 trials

Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00807053·480 enrolled

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT01010971·671 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Ciclesonide HFA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ciclesonide HFA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ciclesonide HFA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sumitomo Pharma America, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sumitomo Pharma America, Inc.

Ciclesonide HFA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Rhinitis3 trials

Seasonal Allergic Rhinitis2 trials

References

Drug Info

Quick Facts

Related News